Pelacarsen

Phase 3RNA therapy

Novartis

Pelacarsen is one of 132 small molecule programs targeting Aortic Stenosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

131

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic StenosisRecruiting

Myocardial InfarctionActive, not recruiting

Cardiovascular DiseaseRecruiting

Atherosclerotic Cardiovascular DiseaseRecruiting

CARActive, not recruiting

Aortic StenosisPhase 2

Recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Cardiovascular DiseasePhase 3

Recruiting

Atherosclerotic Cardiovascular DiseasePhase 3

Recruiting

CARPhase 3

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Cardene

Sun Pharmaceutical Industries, Inc.

Corlanor

Primacor

Geodon

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Colcrys

1 9

Cagrilintide

Novo Nordisk

Phase 3

1 10

Pelacarsen

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

NCT06813911

Q3 2028

Phase 3Active, not recruiting

CAR

NCT05900141

Q1 2030

Phase 3Recruiting

Cardiovascular Disease

NCT07517263

Phase 2Recruiting

Aortic Stenosis

NCT05646381

Q4 2030

Phase 3Recruiting

Atherosclerotic Cardiovascular Disease

NCT06875973

Clinical

Trials by Indication[1]

CAR1 trial

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT05900141·41 enrolled

Hepatic Impairment1 trial

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Completed· Novartis logo

Novartis·Phase 1·NCT05026996·17 enrolled

Myocardial Infarction1 trial

Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

Withdrawn·UUniversity Medical Centre Ljubljana·N/A·NCT04993664

Tics1 trial

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 1·NCT05337878·29 enrolled

Aged1 trial

Managed Access Programs for TQJ230, Pelacarsen

Available· Novartis logo

Novartis··NCT07000695

5 more indications

Cardiovascular Disease1 trial

A Single Arm, Multicenter, Open-label Extension (OLE) Trial to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Participants Who Completed the Parent Lp(a)HORIZON Trial

Recruiting· Novartis logo

Novartis·Phase 3·NCT07517263·5,700 enrolled

Atherosclerotic Cardiovascular Disease (ASCVD)1 trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)

Recruiting· Novartis logo

Novartis·Phase 3·NCT06813911·340 enrolled

Atherosclerotic Cardiovascular Disease1 trial

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD

Recruiting· Novartis logo

Novartis·Phase 3·NCT06875973·599 enrolled

Hyperlipoproteinemia(a)1 trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in Germany

Completed· Novartis logo

Novartis·Phase 3·NCT05305664·51 enrolled

Aortic Stenosis1 trial

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

Recruiting· Novartis logo

Novartis·Phase 2·NCT05646381·502 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Pelacarsen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pelacarsen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pelacarsen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Novartis

Pelacarsen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q1 2030

Q4 2030

Trials by Indication[1]

CAR1 trial

Hepatic Impairment1 trial

Myocardial Infarction1 trial

Tics1 trial

Aged1 trial

Cardiovascular Disease1 trial

Atherosclerotic Cardiovascular Disease (ASCVD)1 trial

Atherosclerotic Cardiovascular Disease1 trial

Hyperlipoproteinemia(a)1 trial

Aortic Stenosis1 trial

References

Drug Info

Quick Facts

Related News